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Purpose: Dexmedetomidine, a full agonist of α2B-adrenoceptors, is used for analge-
sia and sedation in the intensive care units. Dexmedetomidine produces an initial 
transient hypertension due to the activation of post-junctional α2B-adrenoceptors on 
vascular smooth muscle cells (SMCs). The aims of this in vitro study were to identi-
fy mitogen-activated protein kinase (MAPK) isoforms that are primarily involved in 
full, α2B-adrenoceptor agonist, dexmedetomidine-induced contraction of isolated rat 
aortic SMCs. Materials and Methods: Rat thoracic aortic rings without endotheli-
um were isolated and suspended for isometric tension recording. Cumulative dexme-
detomidine (10-9 to 10-6 M) dose-response curves were generated in the presence or 
absence of extracellular signal-regulated kinase (ERK) inhibitor PD 98059, p38 
MAPK inhibitor SB 203580, c-Jun NH2-terminal kinase (JNK) inhibitor SP 600125, 
L-type calcium channel blocker (verapamil and nifedipine), and α2-adrenoceptor in-
hibitor atipamezole. Dexmedetomidine-induced phosphorylation of ERK, JNK, and 
p38 MAPK in rat aortic SMCs was detected using Western blotting. Results: SP 
600125 (10-6 to 10-5 M) attenuated dexmedetomidine-evoked contraction in a con-
centration-dependent manner, whereas PD 98059 had no effect on dexmedetomi-
dine-induced contraction. SB 203580 (10-5 M) attenuated dexmedetomidine-induced 
contraction. Dexmedetomidine-evoked contractions were both abolished by atipa-
mezole and attenuated by verapamil and nifedipine. Dexmedetomidine induced 
phosphorylation of JNK and p38 MAPK in rat aortic SMCs, but did not induce 
phosphorylation of ERK. Conclusion: Dexmedetomidine-induced contraction in-
volves a JNK- and p38 MAPK-mediated pathway downstream of α2-adrenoceptor 
stimulation in rat aortic SMCs. In addition, dexmedetomidine-induced contractions 
are primarily dependent on calcium influx via L-type calcium channels.
Key Words:    Dexmedetomidine, mitogen-activated protein kinase, α2B-adrenocep-
tors, hypertension, rat aorta
INTRODUCTION
The highly selective α2-adrenergic agonist dexmedetomidine has a relative α2/α1 
selectivity ratio of 1,620, which is 5-10 times greater than that of other compounds Dexmedetomidine and JNK Activation 
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by the Institutional Animal Care and Use Committee at 
Gyeongsang National University. 
Preparation of aortic rings for tension measurements
Male Sprague Dawley rats weighing 250-350 g each were 
anesthetized by intraperitoneal administration of pentobar-
bital sodium (50 mg/kg). The aortic rings for tension mea-
surement were prepared according to the method described 
in the previous studies.18,19 The descending thoracic aorta 
was dissected free, and surrounding connective tissues and 
fat were removed under microscopic guidance while aorta 
was bathed in Krebs solution composed of following com-
ponents: 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 
mM KH2PO4, 2.4 mM CaCl2, 25 mM NaHCO3, 11 mM 
glucose, and 0.03 mM EDTA. The aorta was then cut into 
2.5-mm rings and suspended on Grass isometric transduc-
ers (FT-03, Grass Instrument, Quincy, MA, USA) under a 
3.0-g resting tension in a 10-mL Krebs bath at 37°C, aerat-
ed continuously with 95% O2 and 5% CO2 to maintain pH 
values within the 7.35-7.45 range. The rings were equili-
brated at a 3.0-g resting tension for 120 min, during which 
time bathing solution was changed every 30 min. In all aor-
tic rings, the endothelium was intentionally removed from 
the aortic rings by inserting a 25-gauge needle into the lu-
men of the rings and gently rubbing the ring for a few sec-
onds. When the contraction in response to phenylephrine 
(10-7 M) had stabilized, endothelial removal was confirmed 
by the absence of a relaxation response to acetylcholine (10-5 
M). The contractile response evoked by isotonic 30 mM 
KCl was measured for all aortic rings and used as a refer-
ence value. The isotonic 30 mM KCl solution was prepared 
by replacing the NaCl in the Krebs solution with an equi-
molar amount of KCl. After washing out the KCl from the 
organ bath and allowing the isometric tension to return to 
baseline, a cumulative concentration-response curve to ei-
ther dexmedetomidine or levomedetomidine was obtained 
as described below. A single ring was used for each concen-
tration-response curve. The cyclooxygenase inhibitor indo-
methacin (10-5 M) and the nitric oxide synthase inhibitor 
NW-nitro-L-arginine methyl ester (L-NAME, 10-5 M) were 
also included in the Krebs solution to prevent the release of 
endogenous prostaglandins and nitric oxide, respectively, 
from any residual endothelium.  
Experimental protocol
The first series of experiments assessed the cumulative con-
centration-response curves to the medetomidine enantio-
(e.g., α2/α1 selectivity ratio: clonidine, 220; UK 14304, 300).1 
Dexmedetomidine is a full agonist of α2B-adrenoceptors and 
a partial agonist of α2A- and α2C-adrenoceptors.2 In humans 
and mammals, dexmedetomidine produces an initial tran-
sient increase in blood pressure after intravenous injec-
tion.3-8 In addition, intravenous doses of dexmedetomidine 
produce transient systemic and coronary vasoconstriction.6-8 
Activation of post-junctional α2B-adrenoceptors on vascular 
smooth muscle is responsible for the initial transient hyper-
tension.9,10 
In response to receptor stimulation, Ca2+ is mobilized from 
intracellular stores and/or the extracellular space to increase 
cytosolic Ca2+ concentrations in vascular smooth muscle 
cells (SMCs), leading to the activation of the Ca2+-calmodu-
lin-myosin light chain kinase (MLCK) pathway.11 In addition 
to increased cytosolic Ca2+-induced contraction, contraction 
mediated by protein kinases involving Rho-kinase, protein 
kinase C (PKC), mitogen-activated protein kinase (MAPK), 
and receptor tyrosine kinase is believed to play important 
roles in agonist-induced contraction.11,12 Such protein kinase-
mediated contraction leads to the phosphorylation of 20-kDa 
myosin regulatory light chain (MLC20) and inhibition of my-
osin light chain phosphatase (MLCP).11,12 MAPKs are serine-
threonine protein kinases that consist of three isoforms: ex-
tracellular signal-regulated kinase (ERK), p38 MAPK, and 
c-Jun NH2-terminal kinase (JNK).13 A growing body of evi-
dence demonstrates that MAPK pathway activation via G 
protein-coupled receptors is involved in the modulation of 
contraction in vascular smooth muscle.14,15 ERK contributes 
to contractions induced by the partial α2B-adrenoceptor ago-
nist UK 14304 in blood vessles.16,17 As peripheral vasocon-
striction in response to α2-agonists primarily involves the α2B-
adrenoceptor, MAPK isoforms activated by α2-adrenergic 
agonists may differ for each α2-adrenoceptor agonist, de-
pending on the agonist’s affinity for the α2B- adrenoceptor 
subtype.2,9,10 However, from the best knowledge available to 
the authors, the MAPK isoform principally involved in the 
dexmedetomidine-induced contraction in isolated rat aortic 
SMCs has not been previously identified. The goal of the 
current in vitro study was to identify the MAPK isoform that 
is mainly involved in the dexmedetomidine-induced contrac-
tion of isolated rat aortic SMCs.
MATERIALS AND METHODS
All experimental procedures and protocols were approved Seong-Ho Ok, et al.
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night prior to treatment.
Western blot analysis 
Western blot analysis was performed according to the meth-
od described in the previous study.21 In brief, the cells were 
lysed in PRO-PREP protein extract solution for total cell 
lysates, and the lysates were centrifuged at 100,000×g for 
20 min at 4°C. Protein concentration was determined using 
the Bradford method. For preparation of sample loading, 
equal volumes of 2×sodium dodecyl sulfate (SDS) sample 
buffer (0.1 mol/L Tris-HCI, 20% glycerol, 4% SDS, and 
0.01% bromophenol blue) and supernatant fractions from 
the lysates were mixed. Proteins (60 microgram) were sep-
arated by 10% SDS-polyacrylamide gel electrophoresis for 
90 min at 110 V. The separated proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes for 2 h at 20 
mA using SD Semi-dry Transfer Cells (Bio-Rad Laborato-
ries, Hercules, CA, USA). After blocking the membranes 
using 5% nonfat milk in Tris-buffed saline (TBS, pH 7.0), 
the membranes were incubated overnight at 4°C with spe-
cific antibodies at a dilution of 1 : 500 in 5% skim milk in 
TBS-T. Bound antibody was detected by horseradish per-
oxidase (HRP)-conjugated anti-goat or anti-rabbit IgG. The 
membranes were washed and developed using a Western 
Blotting Luminol Reagent System (iNtRON Biotechnolo-
gy, Houston, TX, USA) and autoradiography. 
Drugs
All drugs were of the highest purity available commercially: 
acetylcholine, L-NAME, indomethacin, verapamil, nifedip-
ine, PD 98059, SB 203580, and SP 600125 were obtained 
from Sigma-Aldrich (St. Louis, MO, USA). Dexmedetomi-
dine, levomedetomidine, and atipamezole were kind gifts 
from Orion Pharma (Turku, Finland). All concentrations 
are expressed as the final molar concentration in the organ 
bath. DMEM, FBS, penicillin, streptomycin, trypsin/EDTA, 
and glutamine were supplied by Gibco BRL (Rockville, MD, 
USA). PRO-PREP protein extract solution and electroche-
miluminescence (ECL) Western blotting detection reagents 
were supplied by iNtRON Biotechnology (Houston, TX, 
USA). Anti-phospho-ERK and anti-ERK antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). Anti-phospho-JNK, anti-JNK, anti-phospho-
p38 MAPK, and anti-p38 MAPK antibodies were obtained 
from Cell Signaling Technology (Beverly, MA, USA). Nife-
dipine, PD 98059, SB 203580, and SP 600125 were dis-
solved in dimethyl sulfoxide (DMSO) (final organ bath 
mers dexmedetomidine or levomedetomidine (10-9 to 10-6 
M) in the endothelium-denuded rings. A subsequent con-
centration of dexmedetomidine was added after the previ-
ous concentration elicited a sustained and stable contraction 
for 5 min.   
The second series of experiments was designed to deter-
mine which isoform of MAPK is functionally important in 
mediating dexmedetomidine-induced contraction. The effect 
of MAPK inhibitors (ERK inhibitor: 10-5 M PD 98059, p38 
MAPK inhibitor: 10-6 and 10-5 M SB 203580, JNK inhibitor: 
10-6, 3×10-6, and 10-5 M SP 600125) on the dexmedetomidine 
concentration-response curve was assessed by comparing 
each dexmedetomidine-induced contraction in the presence 
or absence of each MAPK inhibitor. The incubation period 
for each MAPK inhibitor was 20 min prior to addition of dex-
medetomidine. Inhibitor concentrations were chosen based 
on the reported 50% inhibitory concentration.12,20  
The third series of experiments was designed to examine 
the effect of dexmedetomidine on the voltage-operated cal-
cium channel-induced contraction. The initial baseline re-
sponse induced by isotonic 30 mM KCl was recorded in the 
endothelium-denuded aorta. After washing out KCl from 
the organ bath and allowing it to return to the baseline rest-
ing tension, the second isotonic 30 mM KCl-induced con-
traction in the same aorta was determined by adding 30 mM 
KCl solution containing dexmedetomidine (0, 3×10-8, 10-7, 
3×10-7, or 10-6 M) to the organ bath.
Finally, the effects of the L-type calcium channel blocker 
(10-5 M verapamil and 5×10-6 M nifedipine) and the α2-
adrenoceptor antagonist atipamezole (10-4 M) on the dex-
medetomidine concentration-response curve were assessed 
by comparing cumulative dexmedetomidine concentration-
response curves in the presence and absence of each inhibi-
tor. Each inhibitor was added to the organ bath 20 min prior 
to the addition of dexmedetomidine. 
Cell culture
The cells were isolated from the rat thoracic aorta by enzy-
matic dissociation and grown in Dulbecco’s modified eagle 
medium (DMEM) supplemented with 10% heat-inactivat-
ed fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/
mL penicillin, and 100 μg/mL streptomycin. The cells were 
subcultured twice a week by harvesting with trypsin/EDTA 
and seeding in 7.5×105 /mm2 flasks. For experiments, the 
cells between passage numbers 2 and 10 were seeded into 
dishes (2 cells/mm2), fed every other day, and used at con-
fluence (6-7 days). The cells were deprived of serum over-Dexmedetomidine and JNK Activation 
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RESULTS
           
Dexmedetomidine produced concentration-dependent con-
tractions in endothelium-denuded rings (p<0.001: 10-7 to 
10-6 M versus 10-9 M), whereas levomedetomidine produced 
no contractile response (maximal contraction: p<0.001 ver-
sus dexmedetomidine) (Fig. 1). 
The ERK inhibitor PD 98059 (10-5 M), p38 MAPK inhibi-
tor SB 203580 (10-5 M), and JNK inhibitor SP 600125 (10-5 
M) did not significantly affect the baseline resting tension. PD 
98059 (10-5 M) had no effect on dexmedetomidine-induced 
contraction (Fig. 2A). SB 203580 (10-5 M) attenuated dexme-
detomidine-induced maximal contractions (maximal contrac-
tion: p<0.001 versus no drug) (Fig. 2B). SP 600125 (10-6, 
3×10-6, and 10-5 M) attenuated dexmedetomidine-induced 
maximal contractions in a concentration-dependent manner 
(maximal contraction: p<0.001 versus no drug) (Fig. 2C). 
Dexmedetomidine (3×10-8 to 10-6 M) increased 30 mM 
KCl-induced contraction (3×10-8 and 3×10-7 M: p=0.002 
versus no drug; 10-7 M: p=0.001 versus no drug; 10-6 M: 
p=0.006 versus no drug) (Fig. 3A). The maximum contrac-
tile effect of dexmedetomidine in endothelium-denuded 
rings was markedly attenuated by verapamil (10-5 M) and 
nifedipine (5×10-6 M) relative to responses in the absence of 
each inhibitor (maximal contraction: p<0.001 versus no 
drug) (Fig. 3B, C). Dexmedetomidine-induced contractions 
were completely abolished by atipamezole (10-4 M) (maxi-
mal contraction: p<0.001 versus no drug) (Fig. 3B). 
The above results (Fig. 2) indicate the involvement of JNK 
and p38 MAPK in dexmedetomidine-induced contractions. 
Thus, we examined whether dexmedetomidine (10-7 and 10-6 
M) induces activation of JNK and p38 MAPK pathways in 
rat aortic SMCs (Fig. 4A). JNK phosphorylation was induced 
at both 5 minutes and 10 minutes by dexmedetomidine (10-6 
M) (Fig. 4A). p38 MAPK phosphorylation was induced at 
10, 30, and 60 minutes by dexmedetomidine (10-6 M) (Fig. 
4A). As expected, the ERK1/2 pathway was not activated at 
5, 10, 30 and 60 minutes by dexmedetomidine (10-7 or 10-6 
M) (Fig. 4A). Fig. 4B shows that dexmedetomidine (10-6 M) 
treatment induced phosphorylation of p38 and JNK, but not 
ERK1/2, at 10 minutes compared to control (0 minute). 
DISCUSSION
Despite the increased use of dexmedetomidine for analge-
concentration: 0.1% DMSO) as was indomethacin. Unless 
stated otherwise, all other drugs were dissolved and diluted 
in distilled water.
Data analysis
Values are expressed as the mean±SD of n rats from which 
descending thoracic aortic rings were obtained. Contractile 
responses to dexmedetomidine and levomedetomidine are 
expressed as a percentage of the maximum contraction to 
30 mM isotonic KCl. Maximal contraction was defined as 
the contractile response to 10-6 M dexmedetomidine. Statis-
tical analysis for the comparison of maximal contractions 
between the no-drug and inhibitor-treated groups was per-
formed using the Student’s t-test for paired samples or a 
one-way analysis of variance (ANOVA) by Tukey’s multi-
ple comparison test. Band intensities from the Western blot 
analyses were assessed by scanning densitometry, and sta-
tistical analysis was performed using the Mann-Whitney U 
test. Scanning densitometry was performed using an Image 
Master® VSD (Pharmacia Biotech Inc., San Francisco, CA, 
USA). The effect of dexmedetomidine on the 30 mM KCl-
induced contraction was analyzed by an unpaired Student’s 
t-test. Responses to each concentration of dexmedetomidine 
were compared using repeated measures ANOVA followed 
by a Tukey’s multiple comparison test. A p value of less 
than 0.05 was considered statistically significant. 
Fig. 1. Medetomidine enantiomers concentration-response curves in endo-
thelium-denuded rings. Data represent the mean±SD and are expressed as 
the percentage of the maximal contraction induced by isotonic 30 mM KCl 
(isotonic 30 mM KCl-induced contraction: 100%=2.30±0.60 g [n=8] and 
100%=1.90±0.20 g [n=8] for endothelium-denuded rings with dexmedetomi-
dine and levomedetomidine, respectively). *p<0.001 compared with 10
-9 M 
dexmedetomidine. Maximal contraction: †p<0.001 compared with levome-
detomidine.
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Fig. 2. Effects of PD 98059 (10
-5 M), SB 203580 (10
-6, 10
-5 M), and SP 600125 (10
-
6, 3×10
-6, and 10
-5 M) on dexmedetomidine concentration-response curves 
in endothelium-denuded rings. All data represent the mean±SD and are ex-
pressed as the percentage of the maximal contraction induced by isotonic 
30 mM KCl. (A) Isotonic 30 mM KCl-induced contraction: 100%=2.42±0.63 g 
(n=6) and 100%=2.51±0.21 g (n=6) for endothelium-denuded rings with no 
drug and 10
-5 M PD 98059-pretreated endothelium-denuded rings, respec-
tively. (B) Isotonic 30 mM KCl-induced contraction: 100%=2.57±0.29 g (n=7), 
100%=2.81±0.30 g (n=6), and 100%=2.21±0.52 g (n=7) for endothelium-de-
nuded rings with no drug and SB 203580 (10
-6 M)- and (10
-5 M)-pretreated 
endothelium-denuded rings, respectively. Maximal contraction: *p<0.001 
compared with no drug. (C) Isotonic 30 mM KCl-induced contraction: 
100%=2.50±0.42 g (n=7), 100%=2.43±0.42 g (n=6), 100%=2.34±0.29 g (n=7) 
and 100%=2.50±0.31 g (n=5) for endothelium-denuded rings with no drug 
and SP 600125 (10
-6 M)-, (3×10
-6 M)-, and (10
-5 M)-pretreated endothelium-de-
nuded rings, respectively. Maximal contraction: *p<0.001 compared with 
no drug, †p<0.001 compared with 10
-6 M SP 600125, ‡p<0.001 compared with 
3×10
-6 M SP 600125.
Fig. 3. (A) Effect of dexmedetomidine (DMT, 3×10
-8, 10
-7, 3×10
-7, 10
-6 M) on 30 
mM potassium chloride (KCl)-induced contraction in endothelium-denuded 
aorta. Data represent the mean±SD and are expressed as the relative per-
centage of the maximal contraction induced by initial 30 mM KCl 
(100%=2.75±0.48 g [n=6], 100%=2.71±0.78 g [n=6], 100%=2.83±0.47 g [n=6], 
100%=2.68±0.45 g [n=6] and 100%=2.41±0.28 g [n=5] for endothelium-denud-
ed aorta with no drug, 3×10
-8 DMT, 10
-7 DMT, 3×10
-7 DMT and 10
-6 M DMT, 
respectively). *p=0.002, †p=0.001, ‡p=0.002 and §p=0.006 compared with no 
drug. (B) Effects of verapamil and atipamezole on dexmedetomidine con-
centration-response curves in endothelium-denuded rings. Data represent 
the mean±SD and are expressed as the percentage of the maximal con-
traction induced by isotonic 30 mM KCl (isotonic 30 mM KCl-induced contrac-
tion: 100%=2.37±0.53 g [n=6], 100%=2.64±0.59 g [n=5] and 100%=1.47±0.24 g 
[n=5] for endothelium-denuded rings with no drug, the verapamil (10
-5 M)- 
and atipamezole (10
-4 M)-pretreated endothelium-denuded rings, respec-
tively). Maximal contraction: *p<0.001 compared with no drug. (C) Effects of 
nifedipine on dexmedetomidine concentration-response curves in endo-
thelium-denuded rings. Data represent the mean±SD and are expressed as 
the percentage of the maximal contraction induced by isotonic 30 mM KCl 
(isotonic 30 mM KCl-induced contraction: 100%=2.44±0.51 g [n=6] and 
100%=2.45±0.48 g [n=6] for endothelium-denuded rings with no drug and 
the nifedipine (5×10
-6 M)-pretreated endothelium-denuded rings, respec-
tively). Maximal contraction: *p<0.001 compared with no drug. 
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sia and sedation in intensive care units, we believe that the 
present study is the first to investigate the specific MAPK 
isoforms involved in dexmedetomidine-induced contrac-
tions of rat aortic SMCs.22 The major findings of the present 
study are as follows: 1) SP 600125 and SB 203580 attenu-
ated dexmedetomidine-induced contractions, whereas PD 
98059 had no effect on dexmedetomidine-induced contrac-
tions; 2) dexmedetomidine induced phosphorylation of 
JNK and p38 MAPK, whereas dexmedetomidine had no 
effect on ERK phosphorylation; 3) dexmedetomidine-in-
duced contractions were attenuated by the L-type calcium 
channel antagonist (verapamil and nifedipine), indicating a 
role for extracellular Ca2+; these contractions were virtually 
abolished by a high concentration of the α2-adrenoceptor 
antagonist atipamezole.
The L-isomer of medetomidine has no effect on hemody-
namics.3 In agreement with a previous study by Schmeling, 
et al.,3 levomedetomidine failed to contract endothelium-de-
nuded rings, suggesting that the effect of dexmedetomidine 
is stereoselective. 
Protein kinases, including Rho-kinase, PKC, and MAPK, 
mediate agonist-induced contractions.11,12 Three major MAPK 
families have been identified (i.e., ERK, JNK, and p38 
MAPK) in vascular SMCs.13 Several lines of evidence sug-
gest that the ERK-dependent MAPK pathway is activated 
by receptor agonists such as phenylephrine, angiotensin II, 
and 5-hydroxytryptamine, producing contraction of vascu-
lar smooth muscle.23-25 PD 98059 has been shown to attenu-
ate contractions in response to UK 14304 in isolated endo-
thelium-denuded rat aorta and porcine palmar lateral veins, 
suggesting that UK 14304-induced contractions involve 
ERK pathway activation.16,17 In contrast with previous re-
ports, PD 98059 did not alter the dexmedetomidine concen-
tration-response curve in this study, while dexmedetomidine-
induced contractions were attenuated by SP 600125 and SB 
203580, suggesting that the JNK and p38 MAPK pathways 
are involved in dexmedetomidine-induced contractions.16,17 
In addition, both postsynaptic α2A- and α2B-adrenoceptors 
are present in rat aortas.26 This finding may be due to differ-
ences in α2-adrenoceptor subtype affinities, α2-adrenoceptor 
subtype distributions, incubation period and α2//α1 selectivi-
ty ratios, as well as the fact that the α2B-adrenoceptor is the 
main α2-adrenoceptor subtype involved in vascular smooth 
muscle contraction.1,2,9,10,27 However, as SP 600125 also non-
specifically inhibits MLCK, which is involved in vascular 
smooth muscle contraction, we cannot rule out the possibility 
that the inhibition of MLCK induced by SP 600125 may at-
P-ERK1/2
ERK1/2
p-p38
p38
p-JNK
JNK
0 5 10 30 60 5 10 30 60 (min)
DMT (10
-7 M) DMT (10
-6 M)
Fig. 4. Effect of dexmedetomidine (DMT) on the activation of exracellular 
signal-regulated kinase (ERK), p38 mitogen-activated protein kinase 
(MAPK), and c-Jun NH2-terminal kinase (JNK) in rat aortic vascular 
smooth muscle cells (VSMCs). VSMCs were treated with DMT (10
-7 or 10
-6 
M) in a time-dependent manner (5, 10, 30, or 60 min). (A) Phosphorylation of 
ERK, p38 MAPK, and JNK was examined by Western blot analysis as de-
scribed in the methods. (B) Band intensities at 10 min after 10
-6 M dexme-
detomidine pretreatment were assessed by scanning densitometry. Data 
are presented as the mean±SD of three independent experiments. *p= 
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detomidine is a full agonist of α2B-adrenoceptors, whereas 
UK 14304 is a partial agonist of α2B-adrenoceptors.2 Thus, 
this finding may be due to differences in α2-adrenoceptor 
subtype affinities and species.2 As SP 600125 attenuated 
dexmedetomidine-induced maximal contractions in a con-
centration-dependent manner, these results suggest that dex-
medetomidine-induced contraction is primarily mediated by 
activation of a JNK-mediated pathway and, in part, by activa-
tion of a p38 MAPK-mediated pathway. There are several cross 
talk points among the signal transduction pathways of protein 
kinase-mediated contraction.12 Therefore, it is very difficult 
to fully elucidate the signaling pathways involving JNK 
and p38 MAPK that are responsible for dexmedetomidine-
induced contractions. 
Dexmedetomidine produces an initial transient increase 
in blood pressure, followed by a long-lasting reduction in 
blood pressure in both humans and animals.3-8,35 This initial, 
transient increase in blood pressure may be ascribed to the 
time differences between the direct binding of dexmedeto-
midine on α2B-adrenoceptors of vascular SMCs and the dif-
fusion of dexmedetomidine into the central nervous system 
to decrease sympathetic activity; these time differences might 
be unavoidable effects of dexmedetomidine and may be as-
sociated with both dosage and intravenous injection speed.4,5 
Oral and buccal administration of dexmedetomidine in hu-
mans did not produce initial transient hypertension, sug-
gesting that these time differences were eliminated.36,37 In 
the current study, a dexmedetomidine concentration (10-8 
M) that corresponds approximately to the plasma concen-
tration (2×10-9 to 8×10-9 M) of dexmedetomidine used for 
sedation in humans did not produce any contractile re-
sponses, but supraclinical doses (10-7 to 10-6 M) of dexme-
detomidine did so.38 However, any clinical implication of 
dexmedetomidine on regional hemodynamics must be tem-
pered by the fact that the aorta was used in this in vitro ex-
periment, whereas organ blood flow is controlled by chang-
es in the diameters of arterioles with diameters less than 
150 μm. Despite this limitation, taking into consideration 
results from previous studies, as well as the current results, 
these findings suggest that dexmedetomidine-induced JNK- 
and p38 MAPK-mediated contraction may contribute to the 
initial transient increase in blood pressure after dexmedeto-
midine infusion.3-8,35 Dexmedetomidine-induced contrac-
tions in vascular smooth muscle are primarily attenuated by 
endothelial nitric oxide produced via stimulation of endo-
thelial α2-adrenoceptors by dexmedetomidine.29,32,39 Taken 
together, these results suggest that patients, with compro-
tenuate dexmedetomidine-induced contraction.28 Thus, we 
should be very cautious about interpreting data using SP 
600125 as inhibitor of JNK. If a potent and specific inhibi-
tor that is selective for JNK can be developed, further study 
using this selective inhibitor will be needed. 
Dexmedetomidine and clonidine enhance high potassium-
induced contractions in isolated endothelium-denuded ves-
sels.29,30 In accordance with previous studies, dexmedetomi-
dine augmented 30 mM KCl-induced contractions in this in 
vitro study, suggesting that dexmedetomidine has a synergis-
tic effect on voltage-operated calcium channel-induced con-
traction.29,30 Verapamil and nifedipine attenuated contractile 
responses to dexmedetomidine, suggesting that dexmedeto-
midine-induced contraction involves L-type calcium chan-
nels activation. These results indicate that the major signaling 
mechanism for dexmedetomidine-induced contractions is as-
sociated with the Ca2+-calmodulin-MLCK pathway. Howev-
er, although verapamil attenuated dexmedetomidine-induced 
contraction, we could not rule out the possibility that the in-
hibition of α2-adrenoceptors induced by verapamil may at-
tenuate dexmedetomidine-induced contraction because 
verapamil can also bind to α2-adrenoceptors.31 Another L-
type calcium channel blocker, nifedipine, which does not 
compete for [3H] yohimbine binding to alpha-2 adrenocep-
tors, attenuated dexmedetomidine-induced contraction, in-
dicating a significant role for extracellular Ca2+ entry through 
L-type calcium channels in the calcium-dependent mecha-
nism for dexmedetomidine-induced contraction.31 Dexme-
detomidine-induced contractions of rat aortas involve acti-
vation of the lipoxygenase pathway.32 Metabolites generated 
by the lipoxygenase pathway greatly accelerate calcium en-
try, favoring smooth muscle contraction.33 Taken together, 
these results suggest that activation of the lipoxygenase path-
way involved in dexmedetomidine-induced contractions 
may be associated with L-type calcium channel-induced 
contractions in aortic smooth muscle.        
To confirm whether JNK and p38 MAPK mediate dex-
medetomidine-induced contractions, Western blot analyses 
were performed. In agreement with results from isometric 
tension measurements in this in vitro study, dexmedetomi-
dine was shown to induce phosphorylation of both JNK 
and p38 MAPK in rat aortic SMCs, while dexmedetomi-
dine did not induce phosphorylation of ERK. UK 14304-in-
duced contraction increases ERK phosphorylation in por-
cine palmar lateral veins.17 Treatment of the renal tubular cell 
line LLC-PK1-α2B with dexmedetomidine activates ERK via 
a pathway involving arachidonic acid metabolism.34 Dexme-Dexmedetomidine and JNK Activation 
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smooth muscle. Exp Biol Med (Maywood) 2001;226:153-63.
13. Khan TA, Bianchi C, Ruel M, Voisine P, Sellke FW. Mitogen-acti-
vated protein kinase pathways and cardiac surgery. J Thorac Car-
diovasc Surg 2004;127:806-11.
14. Kim B, Kim J, Bae YM, Cho SI, Kwon SC, Jung JY, et al. p38 
mitogen-activated protein kinase contributes to the diminished 
aortic contraction by endothelin-1 in DOCA-salt hypertensive rats. 
Hypertension 2004;43:1086-91. 
15. Lee YR, Lee CK, Park HJ, Kim H, Kim J, Kim J, et al. C-Jun N-
terminal kinase contributes to norepinephrine-induced contraction 
through phosphorylation of caldesmon in rat aortic smooth mus-
cle. J Pharmacol Sci 2006;100:119-25. 
16. Carter RW, Kanagy NL. Tyrosine kinases regulate intracellular 
calcium during alpha (2)-adrenergic contraction in rat aorta. Am J 
Physiol Heart Circ Physiol 2002;283:H1673-80.
17. Roberts RE. Role of the extracellular signal-regulated kinase (Erk) 
signal transduction cascade in alpha (2) adrenoceptor-mediated va-
soconstriction in porcine palmar lateral vein. Br J Pharmacol 2001; 
133:859-66. 
18. Choi YS, Jeong YS, Ok SH, Shin IW, Lee SH, Park JY, et al. The 
direct effect of levobupivacaine in isolated rat aorta involves li-
poxygenase pathway activation and endothelial nitric oxide re-
lease. Anesth Analg 2010;110:341-9.
19. Sung HJ, Sohn JT, Park JY, Hwang EM, Baik JS, Ogawa K. Di-
rect effect of ropivacaine involves lipoxygenase pathway activa-
tion in rat aortic smooth muscle. Can J Anaesth 2009;56:298-306.  
20. Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer 
PL. Alpha-synuclein and its disease-causing mutants induce 
ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. 
FASEB J 2006;20:2000-8. 
21. Park MK, Kang YJ, Lee HS, Kim HJ, Seo HG, Lee JH, et al. The 
obligatory role of COX-2 expression for induction of HO-1 in 
ischemic preconditioned rat brain. Biochem Biophys Res Com-
mun 2008;377:1191-4.
22. Kwak KH. Emergence agitation/delirium: we still don’t know. 
Korean J Anesthesiol 2010;59:73-4. 
23. Dessy C, Kim I, Sougnez CL, Laporte R, Morgan KG. A role for 
MAP kinase in differentiated smooth muscle contraction evoked 
by alpha-adrenoceptor stimulation. Am J Physiol 1998;275:C1081-
6.
24. Touyz RM, EI Mabrouk M, He G, Wu XH, Schiffrin EL. Mito-
gen-activated protein/extracellular signal-regulated kinase inhibi-
tion attenuates angiotensin II-mediated signaling and contraction 
in spontaneously hypertensive rat vascular smooth muscle cells. 
Circ Res 1999;84:505-15. 
25. Watts SW, Yang P, Banes AK, Baez M. Activation of Erk mitogen-
activated protein kinase proteins by vascular serotonin receptors. J 
Cardiovasc Pharmacol 2001;38:539-51. 
26. Civantos Calzada B, Aleixandre de Artiñano A. Alpha-adrenocep-
tor subtypes. Pharmacol Res 2001;44:195-208. 
27. Yildiz O, Ulusoy HB, Seyrek M, Gul H, Yildirim V. Dexmedeto-
midine produces dual alpha 2-adrenergic agonist and alpha 1-ad-
renergic antagonist actions on human isolated internal mammary 
artery. J Cardiothorac Vasc Anesth 2007;21:696-700.
28. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et 
al. The selectivity of protein kinase inhibitors: a further update. 
Biochem J 2007;408:297-315. 
29. Molin JC, Bendhack LM. Clonidine induces rat aorta relaxation 
by nitric oxide-dependent and -independent mechanisms. Vascul 
Pharmacol 2004;42:1-6. 
mised endothelial integrity, such as those with diabetes, hy-
pertension, and atherosclerosis, may exhibit extremely high 
blood pressures due to exaggerated dexmedetomidine-in-
duced vasoconstriction. 
In conclusion, these results indicate that contraction in-
duced by dexmedetomidine involves both JNK- and p38 
MAPK-mediated pathways downstream of α2-adrenoceptor 
stimulation in rat aortic SMCs. In addition, dexmedetomi-
dine-induced contractions are primarily dependent on calci-
um influx via L-type calcium channels.
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